BioNxt Solutions (CSE: BNXT) (OTCQB: XPHYF) (FSE: 4XT) today announced that it has signed a non-binding term sheet for the acquisition of certain intellectual property assets and rights related to a novel solid oral drug dosage form coating delivery technology. “BioNxt is extremely pleased to expand our technology portfolio with an additional drug delivery platform,” said Hugh Rogers, CEO and director of BioNxt. “This novel coating system could significantly improve oral tablet and capsule drug delivery with more precise and predictable dosing. We see a broad range of potential applications from nutritional supplements and over the counter medications to prescription medications and psychedelic compounds.”
To view the full press release, visit https://ibn.fm/pNiVu
About BioNxt Solutions Inc.
BioNxt Solutions is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/BNXT
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
